ACON vs. BACK, BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, and TALKW
Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include IMAC (BACK), Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), and Talkspace (TALKW). These companies are all part of the "healthcare" industry.
Aclarion vs.
IMAC (NASDAQ:BACK) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
In the previous week, Aclarion had 3 more articles in the media than IMAC. MarketBeat recorded 7 mentions for Aclarion and 4 mentions for IMAC. IMAC's average media sentiment score of 0.51 beat Aclarion's score of 0.27 indicating that IMAC is being referred to more favorably in the media.
Aclarion has a consensus target price of $435.50, suggesting a potential upside of 3,493.23%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than IMAC.
Aclarion has lower revenue, but higher earnings than IMAC.
Aclarion received 4 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 80.00% of users gave Aclarion an outperform vote while only 0.00% of users gave IMAC an outperform vote.
IMAC has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
5.8% of IMAC shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
IMAC has a net margin of 0.00% compared to Aclarion's net margin of -12,845.05%. IMAC's return on equity of 0.00% beat Aclarion's return on equity.
Summary
Aclarion beats IMAC on 11 of the 16 factors compared between the two stocks.
Get Aclarion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclarion Competitors List
Related Companies and Tools
This page (NASDAQ:ACON) was last updated on 3/30/2025 by MarketBeat.com Staff
